

Modern Chinese Medicine Group Co., Ltd.
現代中藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)

GLOBAL OFFERING

Total number of Offer Shares : 150,000,000 Shares (subject to the Over-allotment Option)
Number of Hong Kong Public Offering Shares : 15,000,000 Shares (subject to reallocation)
Number of International Placing Shares : 135,000,000 Shares (subject to reallocation and the Over-allotment Option)
Maximum Offer Price : HK\$1.47 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application and subject to refund)
Nominal value : HK\$0.01 per Share
Stock code : 1643

全球發售

發售股份總數目 : 150,000,000 股股份 (視乎超額配股權行使與否而定)
香港公開發售股份數目 : 15,000,000 股股份 (可予重新分配)
國際配售股份數目 : 135,000,000 股股份 (可予重新分配及視乎超額配股權行使與否而定)
最高發售價 : 每股發售股份1.47港元，另加1%經紀佣金、0.0027%證監會交易費及0.005%聯交所交易費 (須於申請時繳足並可予退還)
面值 : 每股股份0.01港元
股份代號 : 1643

Application Form 申請表格

Please read carefully the prospectus of Modern Chinese Medicine Group Co., Ltd. (the "Company") dated 31 December 2020 (the "Prospectus") (in particular, the section "How to apply for Hong Kong Public Offering Shares" in the Prospectus) and the guidelines on the back of this Application Form before completing this Application Form. Terms used in this Application Form shall have the same meanings as those defined in the Prospectus unless defined herein.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange"), Hong Kong Securities Clearing Company Limited ("HKSCC"), the Securities and Futures Commission of Hong Kong ("SFC") and the Registrar of Companies in Hong Kong take no responsibility for the contents of this Application Form, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of this Application Form.

Copies of the Prospectus, all related Application Forms and the other documents specified in "Documents Delivered to the Registrar of Companies and Available for Inspection – Documents Delivered to the Registrar of Companies" in Appendix VI to the Prospectus have been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The SFC and the Registrar of Companies in Hong Kong take no responsibility as to the contents of any of these documents.

Your attention is drawn to the paragraph headed "Personal Information Collection Statement" which sets out the policies and practices of the Company and its Hong Kong Share Registrar in relation to personal data and compliance with the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong).

Nothing in this Application Form or the Prospectus constitutes an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This Application Form and the Prospectus are not for distribution, directly or indirectly, in or into the United States, nor is this application an offer of shares for sale in the United States. The Hong Kong Public Offering Shares have not been and will not be registered under the U.S. Securities Act and may not be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirement under the U.S. Securities Act. No offer of the Offer Shares will be made in the United States.

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. This Application Form and the Prospectus are addressed to you personally. Any forwarding or distribution or reproduction of this Application Form or the Prospectus in whole or in part is unauthorised. Failure to comply with this directive may result in a violation of the U.S. Securities Act or the applicable laws of other jurisdictions.

The allocation of Offer Shares between the Hong Kong Public Offering and the International Placing is subject to reallocation as detailed in the subsection headed "Structure and conditions of the Global Offering – The Hong Kong Public Offering – Reallocation" in the Prospectus. In particular, the Joint Global Coordinators may reallocate Offer Shares from the International Placing to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, the maximum total number of Offer Shares that may be reallocated to the Hong Kong Public Offering following such reallocation shall be not more than double the initial allocation to the Hong Kong Public Offering (i.e. 30,000,000 Shares), and the final price shall be fixed at the low end of the Offer Price range (that is, HK\$0.92 per Offer Share) stated in the Prospectus.

To: Modern Chinese Medicine Group Co., Ltd.
Sole Sponsor
Joint Global Coordinators
Joint Bookrunners
Joint Lead Managers
Co-Lead Managers
Hong Kong Public Offering Underwriters

在填寫本申請表格前，請細閱現代中藥集團有限公司(「本公司」)日期為2020年12月31日的招股章程(「招股章程」)(尤其是招股章程「如何申請香港公開發售股份」一節)及本申請表格背面的指引。除本申請表格另有界定外，招股章程所界定的詞彙在本申請表格具有相同涵義。

香港交易及結算所有限公司、香港聯合交易所有限公司(「聯交所」)、香港中央結算有限公司(「香港結算」)、香港證券及期貨事務監察委員會(「證監會」)及香港公司註冊處處長對本申請表格內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本申請表格全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。

招股章程、所有相關申請表格及招股章程附錄六「送呈公司註冊處處長及備查文件—送呈公司註冊處處長文件」所述的其他文件已遵照香港法例第32章《公司(清盤及雜項條文)條例》第342C條的規定送呈香港公司註冊處處長登記。證監會及香港公司註冊處處長對此等文件的內容概不負責。

閣下務請留意「個人資料收集聲明」一段所載本公司及其香港證券登記處有關個人資料及遵守《個人資料(私隱)條例》(香港法例第486章)的政策及慣例。

本申請表格或招股章程所載者概不構成出售要約或要約購買的游說，而在任何作出有關要約、游說或出售即屬違法的司法管轄區內，概不得出售任何發售股份。本申請表格及招股章程不得在美國境內或向美國直接或間接派發；而此項申請亦非在美國出售股份的要約。香港公開發售股份未曾亦不會根據美國《證券法》登記，除非獲豁免遵守美國《證券法》登記規定或並非受該等登記規定規限的交易，概不得提早發售或出售。發售股份不會在美國提早發售。

在任何根據當地法例不得發送、派發或複製本申請表格及招股章程的司法管轄區內概不得發送或派發或複製(不論方式，也不論全部或部分)本申請表格及招股章程。本申請表格及招股章程僅致予閣下本人。概不得發送或派發或複製本申請表格或招股章程的全部或部分。如未能遵守此項指令，可能違反美國《證券法》或其他司法管轄區的適用法律。

香港公開發售與國際配售之間的發售股份分配可按照招股章程「全球發售的架構及條件—香港公開發售—重新分配」分節所詳述者予以重新分配。具體而言，聯席全球協調人可將發售股份自國際配售重新分配至香港公開發售，以滿足根據香港公開發售提出的有效申請。根據聯交所發佈的指引函HKEX-GL91-18，倘有關重新分配並非根據上市規則(第18項應用指引)進行，則於有關重新分配後，可重新分配至香港公開發售的發售股份總數最多不得超過香港公開發售所作之最初分配的兩倍(即30,000,000股股份)，及最終價格須釐定為招股章程所述發售價範圍的下限(即每股發售股份0.92港元)。

致：現代中藥集團有限公司
獨家保薦人
聯席全球協調人
聯席賬簿管理人
聯席牽頭經辦人
副牽頭經辦人
香港公開發售包銷商

We confirm that we have (i) complied with the Guidelines for Electronic Public Offerings and the Operational Procedures for eIPO Applications submitted via banks/stockbrokers and all applicable laws and regulations (whether statutory or otherwise) in relation to the provision of our **HK eIPO White Form** services in connection with the Hong Kong Public Offering; and (ii) read the terms and conditions and application procedures set out in the Prospectus and this Application Form and agree to be bound by them. Applying on behalf of each of the underlying applicants to whom this application relates, we:

- apply for the number of Hong Kong Public Offering Shares set out below, on the terms and conditions of the Prospectus and this Application Form, and subject to the Memorandum and the Articles of Association;
- enclose payment in full for the Hong Kong Public Offering Shares applied for, including 1% brokerage, 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee;
- confirm that the underlying applicants have undertaken and agreed to accept the Hong Kong Public Offering Shares applied for, or any lesser number allocated to such underlying applicants on this application;
- undertake and confirm that the underlying applicant(s) and the person for whose benefit the underlying applicant(s) is/are applying has/have not applied for or taken up, or indicated an interest for, or received or been placed or allocated (including conditionally and/or provisionally), and will not apply for or take up, or indicate an interest for, any International Placing Shares under the International Placing nor otherwise participate in the International Placing;
- understand that these declarations and representations will be relied upon by the Company, the Sole Sponsor, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Co-Lead Managers and the Underwriters in deciding whether or not to make any allotment of Hong Kong Public Offering Shares in response to this application;
- authorise the Company to place the name(s) of the underlying applicant(s) on the register of members of the Company as the holder(s) of any Hong Kong Public Offering Shares to be allotted to them, and (subject to the terms and conditions set out in this Application Form) to send any Share certificate(s) (where applicable) by ordinary post at that underlying applicant's own risk to the address stated in the application instruction of that underlying applicant in accordance with the procedures prescribed in this Application Form and in the Prospectus;
- request that any e-Auto Refund payment instructions be despatched to the application payment account where the underlying applicants had paid the application monies from a single bank account;
- request that any refund cheque(s) be made payable to the underlying applicant(s) who had used multiple bank accounts to pay the application monies and to send any such refund cheque(s) by ordinary post at that underlying applicant's own risk to the address stated on the application in accordance with the procedures prescribed in this Application Form, in the Prospectus, in the IPO App and on the designated website at www.hkeipo.hk under the HK eIPO White Form service;
- confirm that each underlying applicant has read the terms and conditions and application procedures set out in this Application Form, the Prospectus, the IPO App and the designated website at www.hkeipo.hk under the HK eIPO White Form service and agrees to be bound by them;
- represent, warrant and undertake that the underlying applicants understand that the Shares have not been and will not be registered under the U.S. Securities Act and the underlying applicant and any person for whose benefit the underlying applicant are applying for are outside the United States (as defined in Regulation S) or are a person described in paragraph h(3) of Rule 902 of Regulation S;
- represent, warrant and undertake that allotment of or the application for the Hong Kong Public Offering Shares to the underlying applicants or by underlying applicants or for whose benefit this application is made would not require the Company to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong;
- agree that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong; and
- agree that the Company, the Sole Sponsor, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Co-Lead Managers, the Hong Kong Underwriters and their respective directors, advisors and agents and any other parties involved in the Global Offering are entitled to rely on any warranty, representation or declaration made by us or the underlying applicants.

Signature: 簽名:	
Name of applicant: 申請人姓名/名稱:	

吾等確認，吾等已(i)遵守電子公開發售指引及透過銀行/股票經紀遞交電子首次公開發售申請的操作程序以及與吾等就香港公開發售提供網上白表服務有關的所有適用法律及法規(法定或其他)；及(ii)細閱招股章程及本申請表格所載的條款及條件以及申請手續，並同意受其約束。為代表與本申請有關的各相關申請人提出申請，吾等：

- 按照招股章程及本申請表格的條款及條件，並在組織章程大綱及組織章程細則的規限下，申請認購以下數目的香港公開發售股份；
- 夾附申請認購香港公開發售股份所需的全數款項(包括1%經紀佣金、0.0027%證監會交易費及0.005%聯交所交易費)；
- 確認相關申請人已承諾及同意接納所申請數目或就本申請配發予彼等的任何較少數目的香港公開發售股份；
- 承諾及確認相關申請人及相關申請人為其利益而代為提出申請的人士並無申請或接納或表示有意認購，或收取或轉配或獲分配(包括有條件及/或暫時地)，亦不會申請或接納或表示有意認購國際配售項下的任何國際配售股份或以其他方式參與國際配售；
- 明白 貴公司、獨家保薦人、聯席全球協調人、聯席賬簿管理人、聯席牽頭經辦人、副牽頭經辦人及包銷商將依賴此等聲明及陳述，以決定是否就本申請配發任何香港公開發售股份；
- 授權 貴公司將相關申請人的姓名/名稱列入 貴公司股東名冊內，作為任何將配發予相關申請人的香港公開發售股份的持有人，並(在符合本申請表格所載的條款及條件的情況下)根據本申請表格及招股章程所載程序，按相關申請人的申請指示上所示地址以普通郵遞方式寄發任何股票(如適用)，郵誤風險概由該相關申請人自行承擔；
- (倘相關申請人以單一銀行賬戶支付申請股款) 要求將電子自動退款指示發送至支付申請股款賬戶；
- (倘相關申請人以多個銀行賬戶支付申請股款) 要求退款支票以相關申請人為抬頭人，並根據本申請表格、招股章程、IPO App及網上白表服務指定網站www.hkeipo.hk所述程序將任何有關退款支票以普通郵遞方式寄發到申請所列的地址，郵誤風險概由相關申請人自行承擔；
- 確認各相關申請人已細閱本申請表格、招股章程、IPO App及網上白表服務指定網站www.hkeipo.hk所載的條款及條件以及申請手續，並同意受其約束；
- 聲明、保證及承諾相關申請人明白股份不會亦不會根據美國《證券法》登記且相關申請人及相關申請人為其利益提出申請的任何人士均身處美國境外(定義見S規例)，又或屬S規例第902條h(3)段所述的人士；
- 聲明、保證及承諾向相關申請人或由相關申請人或為其利益而提出本申請的人士配發或申請香港公開發售股份，不會引致 貴公司須遵從香港以外任何地區的任何法律或法規的任何規定(不論是否具法律效力)；
- 同意本申請、任何對本申請的接納及由此產生的合約將受香港法例規管並按其詮釋；及
- 同意 貴公司、獨家保薦人、聯席全球協調人、聯席賬簿管理人、聯席牽頭經辦人、副牽頭經辦人、香港包銷商以及彼等各自的董事、顧問及代理以及參與全球發售的任何其他各方有權依賴吾等或相關申請人作出的任何保證、陳述或聲明。

Date: 日期:	
Capacity: 身份:	

2	We, on behalf of the underlying applicants, offer to purchase 吾等(代表相關申請人)要約購買	Total number of Shares 股份總數	Hong Kong Public Offering Shares on behalf of the underlying applicants whose details are contained in the read-only CD-ROM submitted with this Application Form. 香港公開發售股份(代表相關申請人，其詳細資料載於連同本申請表格遞交的唯讀光碟)。
---	---	-----------------------------	--

3	A total of 現夾附合共	cheque(s) 張支票	Cheque Number(s) 支票編號
is/are enclosed herewith for 總金額為	HK\$		Name of bank 銀行名稱
	港元		

4	Please use BLOCK letters 請用正體填寫		
Name of HK eIPO White Form Service Provider 網上白表服務供應商名稱	HK eIPO White Form Service Provider ID 網上白表服務供應商編號		
Chinese Name 中文名稱	Contact number 聯絡電話號碼	Fax number 傳真號碼	
Name of contact person 聯絡人士姓名	For Broker use 此欄供經紀填寫 Lodged by 申請由以下經紀遞交		
Address 地址	Broker No. 經紀號碼		
	Broker's Chop 經紀印章		
For Bank use 此欄供銀行填寫			

GUIDE TO COMPLETING THIS APPLICATION FORM

References to boxes below are to the numbered boxes on this Application Form.

1 Sign and date the application form in Box 1. Only a written signature will be accepted.

The name and the representative capacity of the signatory should also be stated.

To apply for Hong Kong Public Offering Shares using this Application Form, you must be named in the list of eIPO Service Providers who may provide **HK eIPO White Form** services in relation to the Hong Kong Public Offering, which was released by the SFC.

2 Put in Box 2 (in figures) the total number of Hong Kong Public Offering Shares for which you wish to apply on behalf of the underlying applicants.

Applicant details of the underlying applicants on whose behalf you are applying must be contained in one data file in read-only CD-ROM format submitted together with this Application Form.

3 Complete your payment details in Box 3.

You must state in this box the number of cheques you are enclosing together with this Application Form; and you must state on the reverse of each of those cheques (i) your **HK eIPO White Form** Service Provider ID and (ii) the file number of the data file containing application details of the underlying applicant(s).

The dollar amount(s) stated in this box must be equal to the amount payable for the total number of Hong Kong Public Offering Shares applied for in Box 2.

All cheque(s) and this Application Form together with a sealed envelope containing the CD-ROM, if any, must be placed in the envelope bearing your company chop.

For payments by cheque, the cheque must:

- be in Hong Kong dollars;
- be drawn on a Hong Kong dollar bank account with a licensed bank in Hong Kong;
- show your (or your nominee's) account name;
- be made payable to "BANK OF CHINA (HONG KONG) NOMINEES LIMITED – MODERN CHINESE MEDICINE GROUP PUBLIC OFFER";
- be crossed "Account Payee Only";
- not be post-dated; and
- be signed by the authorised signatories of the **HK eIPO White Form** Service Provider.

Your application may be rejected if any of these requirements is not met or if the cheque is dishonoured on its first presentation.

It is your responsibility to ensure that details on the cheque(s) submitted correspond with the application details contained in the CD-ROM or data file submitted in respect of this application. The Company and the Sole sponsor have full discretion to reject any applications in the case of discrepancies.

The Company and the Joint Global Coordinators have full discretion to reject any applications in the case of discrepancies.

No receipt will be issued for sums paid on application.

4 Insert your details in Box 4 (using BLOCK letters).

You should write the name, ID and address of the **HK eIPO White Form** Service Provider in this box. You should also include the name and telephone number of the contact person at your place of business and where applicable, the Broker No. and Broker's Chop.

Personal Information Collection Statement

The main provisions of the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the "Ordinance") came into effect in Hong Kong on December 20, 1996. This Personal Information Collection Statement informs the applicant for and holder of the Shares of the policies and practices of the Company and the Hong Kong Share Registrar in relation to personal data and the Ordinance.

1 Reasons for the collection of your personal data

From time to time it is necessary for applicants for securities or registered holders of securities to supply their latest correct personal data to the Company and/or its Hong Kong Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the Hong Kong Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected or in delay or inability of the Company and/or the Hong Kong Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfer of the Hong Kong Public Offering Shares which you have successfully applied for and/or the despatch of Share certificate(s) and/or refund cheque(s), and/or e-Auto Refund payment instruction(s) to which you are entitled.

It is important that applicants and holders of securities inform the Company and the Hong Kong Share Registrar immediately of any inaccuracies in the personal data supplied.

2 Purposes

The personal data of the applicants and holders of securities may be used, held and/or stored (by whatever means) for the following purposes:

- processing of your application, e-Auto Refund payment instructions and/or refund cheque and/or e-Auto Refund payment instruction(s), where applicable, and verification of compliance with the terms and application procedures set out in this Application Form and the Prospectus and announcing results of allocations of the Hong Kong Public Offering Shares;
- enabling compliance with all applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of holders of securities including, where applicable, in the name of HKSCC Nominees;
- maintaining or updating the registers of holders of securities of the Company;
- conducting or assisting to conduct signature verifications, any other verification or exchange of information;
- establishing benefit entitlements of holders of securities of the Company, such as dividends, rights issues and bonus issues, etc;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and securities holder profiles;
- making disclosures as required by any laws, rules or regulations;
- disclosing identities of successful applicants by way of press announcement(s) or otherwise;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and the Hong Kong Share Registrar to discharge their obligations to holders of securities and/or regulators and any other purpose to which the holders of securities may from time to time agree.

3 Transfer of personal data

Personal data held by the Company and the Hong Kong Share Registrar relating to the applicants and holders of securities will be kept confidential but the Company and its Hong Kong Share Registrar may, to the extent necessary for achieving the above purposes or any of them, make such enquiries as they consider necessary to confirm the accuracy of the personal data and in particular, they may disclose, obtain, transfer (whether within or outside Hong Kong) the personal data of the applicants and holders of securities to, from or with any and all of the following persons and entities:

- the Company or its appointed agents such as financial advisers, receiving banks and overseas principal share registrar;
- where applicants for securities request deposit into CCASS, to HKSCC and HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company and/or the Hong Kong Share Registrar in connection with the operation of their respective businesses;
- the Stock Exchange, the SFC and any other statutory, regulatory or governmental bodies; and
- any other persons or institutions with which the holders of securities have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers, etc.

4 Retention of personal data

The Company and the Hong Kong Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

5 Access and correction of personal data

The Ordinance provides the applicants and holders of securities with rights to ascertain whether the Company and/or the Hong Kong Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. In accordance with the Ordinance, the Company and the Hong Kong Share Registrar have the right to charge a reasonable fee for the processing of any data access request. All requests for access to data or correction of data or for information regarding policies and practices and the kinds of data held should be addressed to the Company for the attention of the Company secretary or (as the case may be) the Hong Kong Share Registrar for the attention of the Privacy Compliance Officer for the purposes of the Ordinance.

By signing an Application Form, you agree to all of the above.

DELIVERY OF THIS APPLICATION FORM

This completed Application Form, together with the appropriate cheque(s) together with a sealed envelope containing the CD-ROM, must be submitted to the following receiving bank by 4:00 p.m. on Thursday, 7 January 2021:

Bank of China (Hong Kong) Limited
CP2, Bank of China Tower, 1 Garden Road, Hong Kong

填寫本申請表格的指引

下文所述的號碼乃本申請表格中各欄的編號。

1 在申請表格欄1簽署及填上日期。只接納親筆簽名。

簽署人的姓名／名稱及代表身份亦必須註明。

如要使用本申請表格申請認購香港公開發售股份，閣下必須為名列於證監會公佈的電子首次公開發售服務供應商名單內可就香港公開發售提供網上白表服務的人士。

2 在欄2填上 閣下欲代表相關申請人申請認購的香港公開發售股份總數（以數字填寫）。

閣下代其作出申請的相關申請人資料，必須載於連同本申請表格遞交的唯讀光碟格式資料檔案。

3 在欄3填上 閣下的詳細付款資料。

閣下必須在本欄註明 閣下夾附於本申請表格的支票數目；及 閣下必須在每張支票的背面註明(i) 閣下的網上白表服務供應商編號及(ii)載有相關申請人詳細申請資料的資料檔案的檔案編號。

本欄所註明的金額必須與欄2所申請認購的香港公開發售股份總數應付的金額相同。

所有支票及本申請表格，連同裝有光碟的密封信封（如有）必須放入加蓋 閣下公司印章的信封內。

如以支票繳付股款，則該支票必須：

- 為港元；
- 由在香港持牌銀行開設的港元銀行賬戶開出；
- 顯示 閣下（或 閣下代名人）的賬戶名稱；
- 註明抬頭人為「中國銀行（香港）代理人有限公司 — 現代中藥集團公開發售」；
- 劃線註明「只准入抬頭人賬戶」；
- 不得為期票；及
- 由網上白表服務供應商的授權簽署人簽署。

倘未能符合任何此等規定或支票在首次過戶時未能兌現，閣下的申請可能遭拒絕受理。

閣下有責任確保所遞交的支票上的詳細資料與就本申請遞交的光碟或資料檔案所載的申請詳細資料相同。如有差異，本公司及獨家保薦人可全權酌情拒絕任何申請。

倘出現差異，本公司及聯席全球協調人可全權酌情拒絕任何申請。

本公司不會就申請時繳付的款項發出收據。

4 在欄4填上 閣下的詳細資料（以正楷填寫）。

閣下須在本欄填上網上白表服務供應商的名稱、編號及地址。閣下亦須填寫 閣下營業地點的聯絡人士的姓名及電話號碼及（如適用）經紀號碼及經紀印章。

個人資料收集聲明

香港法例第486章《個人資料（私隱）條例》（「《條例》」）的主要條文於1996年12月20日在香港生效。此個人資料收集聲明旨在向股份申請人及持有人說明本公司及香港證券登記處就個人資料及《條例》而制定的政策及慣例。

1 收集 閣下個人資料的原因

證券申請人或證券登記持有人以本身名義申請證券或轉讓或受讓證券時或尋求香港證券登記處的服務時，須不時向本公司及／或香港證券登記處提供最新的正確個人資料。

未能提供所要求的資料可能導致 閣下申請證券被拒或延遲，或本公司及／或香港證券登記處無法落實轉讓或提供服務。此舉也可能妨礙或延遲登記或轉讓 閣下成功申請的香港公開發售股份及／或派發 閣下應得的股票及／或退款支票及／或電子自動退款指示。

證券申請人及持有人提供的個人資料如有任何不正確之處，必須即時知會本公司及香港證券登記處。

2 目的

證券的申請人及持有人的個人資料可以任何方式被採用、持有及／或保存，以作下列用途：

- 處理 閣下的申請、電子自動退款指示及／或退款支票及／或電子自動退款指示（如適用）及核實有否遵守本申請表格及招股章程所載的條款及申請手續及公佈香港公開發售股份的分配結果；
- 確保遵守香港及其他地方的一切適用法律及法規；
- 登記新發行證券或將證券轉入證券持有人名下或由其名下轉讓予他人（包括以香港結算代理人的名義（如適用））；
- 保存或更新本公司證券持有人名冊；
- 核實或協助核實簽名、任何其他核證或交換資料；
- 確定本公司證券持有人的受益權利，例如股息、供股和紅股等；
- 分發本公司及其附屬公司的公司通訊；
- 編撰統計資料及證券持有人資料；
- 遵照任何法例、規則或條例的規定作出披露；
- 透過於報章公佈或其他方式披露成功申請人士的身份；
- 披露有關資料以便提出權益索償；及
- 與上述有關的任何其他附帶或相關目的及／或使本公司及香港證券登記處履行彼等對證券持有人及／或監管機構承擔的責任及證券持有人不時同意的任何其他目的。

3 轉交個人資料

本公司及香港證券登記處所持有關證券申請人及持有人的個人資料將會保密，但本公司及香港證券登記處可以在達到上述目的或當中任何目的之必要情況下，作出彼等認為必要的查詢以確認個人資料的準確性，尤其彼等可向或從下列任何及全部人士和實體或與下列任何及全部人士和實體互相披露、索取或轉交（無論在香港境內或境外）證券申請人及持有人的個人資料：

- 本公司或其委任的代理，如財務顧問、收款銀行及主要海外股份過戶登記處；
- （如證券申請人要求將證券存入中央結算系統）香港結算及香港結算代理人，彼等將會就中央結算系統的運作使用有關個人資料；
- 向本公司及／或香港證券登記處提供與其各自業務營運有關的行政、電訊、電腦、付款或其他服務的任何代理、承包商或第三方服務供應商；
- 聯交所、證監會及任何其他法定、監管或政府機關；及
- 證券持有人與其進行或擬進行交易的任何其他人士或機構，例如彼等的銀行、律師、會計師或股票經紀等。

4 保留個人資料

本公司及香港證券登記處將按收集個人資料所需的用途保留證券申請人及持有人的個人資料。毋須保留的個人資料將會根據《條例》銷毀或處理。

5 查閱和更正個人資料

《條例》賦予證券申請人及持有人權利以確定本公司及／或香港證券登記處是否持有其個人資料，並有權索取該資料的副本及更正任何不正確資料。根據《條例》，本公司及香港證券登記處有權就處理任何查閱資料的要求收取合理費用。就《條例》而言，所有查閱資料或更正資料或查閱有關政策及慣例以及所持資料類別的要求，應向本公司的公司秘書或（視乎情況而定）香港證券登記處的個人資料私隱事務主任提出。

閣下簽署申請表格，即表示同意上述各項。

遞交本申請表格

經填妥的申請表格，連同適用支票及裝有光碟的密封信封，必須於2021年1月7日（星期四）下午四時正前，送達下列收款銀行：

中國銀行（香港）有限公司
香港花園道1號中銀大廈CP2層